注意力不足过动症市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Attention Deficit Hyperactivity Disorder Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年11月04日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球注意力不足过动症市场估值达到 158 亿美元，预计 2024 年至 2032 年复合年增长率将超过 5.1%。开发创新疗法。对过动症的认识和理解不断提高也是促成因素，导致对增强诊断和治疗方案的需求更大。

ADHD 是一种神经发育障碍，其症状包括注意力不集中、过动和衝动，影响儿童和成人。 ADHD 市场涵盖诊断、治疗和管理策略，提供药物治疗、行为介入、诊断工具和支援服务，以改善各年龄层患者的治疗结果。治疗选择多种多样，包括药物和非药物方法，其中主要解决方案是兴奋剂和非兴奋剂药物。

在ADHD 药物市场中，兴奋剂占销售额的大部分，到2023 年价值将达到112 亿美元。衝动控制。虽然兴奋剂因其快速有效而成为过动症治疗的基础部分，但个别化治疗计划和长期监测对于控制潜在副作用和确保持续效益至关重要。非刺激性选择虽然通常效果较差，但为寻求不同方法的患者提供了替代方案。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	158 亿美元
预测值	246 亿美元
复合年增长率	5.1%

该市场按年龄组进行细分，到 2023 年，儿童将占 67.1% 的很大份额。介入措施可能包括行为治疗、教育支持和必要时的药物治疗。

从性别来看，男性主导市场，由于过动和衝动行为更明显，男性在诊断中占很大比例。这种较高的盛行率刺激了有针对性的治疗方法，以解决男性在教育和社会环境中经常面临的独特挑战。

在剂型中，片剂占据最大的市场份额，到2023年将达到92亿美元。零售药局在分销多动症药物方面发挥关键作用，为市场贡献了 93 亿美元，其好处包括便利性、定期处方补充和保险管理支援。

在美国，ADHD 市场预计将以5.1% 的复合年增长率成长，到2032 年将达到102 亿美元。这种成长是由高认知度、治疗保险覆盖以及数位治疗选择创新推动的，从而增加了市场机会。

The Global Attention Deficit Hyperactivity Disorder Market reached a valuation of USD 15.8 billion in 2023 and is anticipated to expand at a CAGR of over 5.1% from 2024 to 2032. This growth is primarily driven by increasing ADHD diagnoses, advancements in diagnostic tools, and the continuous development of innovative treatments. Rising awareness and understanding of ADHD are also contributing factors, leading to greater demand for enhanced diagnosis and treatment options.

ADHD, a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity, affects both children and adults. The ADHD market covers diagnosis, treatment, and management strategies, offering pharmaceutical therapies, behavioral interventions, diagnostic tools, and support services to improve patient outcomes across age groups. Treatment options are diverse, encompassing both pharmacological and non-pharmacological approaches, with stimulant and non-stimulant medications among the primary solutions.

In the ADHD drug market, stimulants account for the majority of sales, valued at USD 11.2 billion in 2023. These medications work by increasing norepinephrine and dopamine levels in the brain, helping improve attention, focus, and impulse control. While stimulants have become a foundational part of ADHD treatment due to their rapid effectiveness, individualized treatment plans and long-term monitoring are essential to manage potential side effects and ensure sustained benefits. Non-stimulant options, though generally less effective, provide alternatives for patients seeking different approaches.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$15.8 Billion
Forecast Value	$24.6 Billion
CAGR	5.1%

The market is segmented by age group, with children representing a substantial share of 67.1% in 2023. Early diagnosis and tailored interventions are vital for children with ADHD, helping them address challenges that impact their academic and social development. Interventions may include behavioral therapy, educational support, and medication as needed.

Gender-wise, males lead the market, with a significant portion of diagnoses due to the more visible nature of hyperactive and impulsive behaviors. This higher prevalence has spurred targeted treatment approaches to address the unique challenges males often face in educational and social environments.

Among dosage forms, tablets hold the largest market share, reaching USD 9.2 billion in 2023. Tablets, including immediate-release and extended-release formulations, allow flexible dosing for both children and adults. Retail pharmacies play a critical role in distributing ADHD medications, contributing USD 9.3 billion to the market, with benefits including convenience, regular prescription refills, and insurance management support.

In the U.S., the ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032. This growth is driven by high awareness, insurance coverage for treatments, and innovations in digital therapeutic options, enhancing market opportunities.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing ADHD diagnosis rates
  - 3.2.1.2 Advancements in pharmaceutical treatments
  - 3.2.1.3 Increased awareness and education
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of ADHD medications
  - 3.2.2.2 Side effects and concerns with medications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Drug Type, 2021-2032 ($ Mn)

5.1 Key trends
5.2 Stimulants
- 5.2.1 Amphetamine
- 5.2.2 Methylphenidate
- 5.2.3 Lisdexamfetamine
- 5.2.4 Dexmethylphenidate
- 5.2.5 Dextroamphetamine
5.3 Non-stimulants
- 5.3.1 Atomoxetine
- 5.3.2 Guanfacine
- 5.3.3 Clonidine
- 5.3.4 Other non-stimulants

Chapter 6 Market Estimates & Forecast, By Age Group, 2021-2032 ($ Mn)

6.1 Key trends
6.2 Children
6.3 Adults

Chapter 7 Market Estimates & Forecast, By Gender, 2021-2032 ($ Mn)

7.1 Key trends
7.2 Male
7.3 Female

Chapter 8 Market Estimates & Forecast, By Dosage Form, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Tablets
8.3 Capsules
8.4 Other dosage forms

Chapter 9 Market Estimates & Forecast, By Distribution Channel, 2021-2032 ($ Mn)

9.1 Key trends
9.2 Retail pharmacy
9.3 Hospital pharmacy
9.4 Online pharmacy

Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
10.6 MEA
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE